Cost-Utility of Repeated Screening for Chlamydia Trachomatis

Mar 1, 2008, 00:00 AM
10.1111/j.1524-4733.2007.00225.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60520-7/fulltext
Section Title :
Section Order : 17
First Page :

Objective

To estimate the cost-effectiveness of repeated screening for chlamydia trachomatis at various time intervals compared to one-off screening of Dutch young adults.

Methods

We used a dynamic model to fully take the spread of the disease over time in the population into account, with data being used gathered within the context of a recently performed pilot study in The Netherlands. The screening frequencies analyzed were: every year, every 2 years, every 5 years, and every 10 years. The strategies were compared in terms of incremental cost-effectiveness, expressed as the net costs per quality-adjusted life-year (QALY).

Results

For all interval strategies, with the exception of screening every year, incremental cost-effectiveness stays below the informal Dutch threshold of €20,000 per QALY.

Conclusion

From a health-economic point of view, for the Dutch situation, we estimated screening every 2 years as the optimal strategy among the options investigated.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60520-7&doi=10.1111/j.1524-4733.2007.00225.x
HEOR Topics :
  • Clinical Trials
  • Cost/Cost of Illness/Resource Use Studies
  • Cost-comparison, Effectiveness, Utility, Benefit Analysis
  • Decision Modeling & Simulation
  • Economic Evaluation
  • Specific Diseases & Conditions
  • Study Approaches
Tags :
  • Chlamydia trachomatis
  • cost-utility analysis
  • dynamic model
  • screening
Regions :
  • Eastern and Central Europe
  • Western Europe